AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 18 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Inoculation with a vaccine that generated an antibody response against human chorionic gonadotropin (hCG) increased survival of patients with colorectal cancer, researchers in the U.S. found.
"Human chorionic gonadotropin (hCG) is produced by colorectal cancer and may play a role in its progression," commented Hong M. Moulten and colleagues at AVI BioPharma, Inc., and the University of Alabama.
Moulton and his collaborators constructed an anti-hCG vaccine by conjugating the carboxyl terminal peptide of beta-hCG (CTP37) to diphtheria toxoid (DT). After formulating CTP37-DT into an emulsion, the investigators administered the vaccine through intramuscular injection at 0, 28, and 70 days to 77 patients with metastatic colorectal cancer. Two dosage regimens were followed.
The vaccine generated a specific anti-hCG antibody response in 56 (73%) of the patients. Median survival was 34 weeks for all vaccinated patients. However, a significant difference in mean survival existed between patients who had anti-hCG antibody levels higher than the median and those with levels lower than the median (45 weeks vs. 24 weeks, p=0.0002).
Neither dose nor anti-DT antibody levels were associated with survival. The vaccine did not ...
Source: HighBeam Research, Vaccine that targets human chorionic gonadotropin extends colorectal...